NAT2 genotype-based isoniazid PopPK studies are required from several parts of the world, particularly from high TB burden Asian countries and western populations, as well as in pediatric and pregnant TB populations for initiating a pharmacogenomic-guided therapy to TB patients for improving clinical outcomes and reducing adverse drug reactions. The gene discussed is NAT2; the disease is tuberculosis.